Clinical Trial: Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferative

Brief Summary: This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802. During this extension study, all patients will receive open-label treatment of octreotide acetate in microspheres every 4 weeks for 2 years for the treatment of moderately severe to severe NPDR and low risk PDR.

Detailed Summary:
Sponsor: Novartis Pharmaceuticals

Current Primary Outcome: long-term safety and tolerability

Original Primary Outcome:

Current Secondary Outcome: monitor long-term efficacy

Original Secondary Outcome:

Information By: Novartis

Dates:
Date Received: November 2, 2005
Date Started: November 2005
Date Completion:
Last Updated: April 8, 2012
Last Verified: April 2012